Downregulation of aromatase by siRNA decreases acetylcholinesterase mRNA and specific activity in SHSY5Y cells

Anti-hormone therapy mediated cognitive decline among cancer patients has been referred to as chemobrain. Current literature indicates that declined estrogen in the brain may be contributing to the genesis of this phenomenon. Aromatase is a key enzyme that converts C19 steroids to estrogen in the brain, although its involvement in cognitive function has remained obscure. This study evaluated the downregulation of aromatase by siRNA treatment and the effect of aromatase downregulation on mRNA expression and specific activity of acetylcholinesterase in SHSY5Y cells. short interfering RNA duplexes were employed to achieve aromatase gene downregulation in SH-SY5Y cells. The reduction of aromatase mRNA was analyzed by real-time PCR. Estradiol levels were determined to confirm the downregulation by a commercial ELISA kit. Acetylcholinesterase mRNA level of siRNA-treated SH-SY5Y cells was analyzed employing Real-time PCR. Specific acetylcholinesterase activity was determined using the Ellman method. Viability and caspase 3/7 activity was examined using ApoTox-GloTM Triplex Assay. zVad-Fmk was employed as a pan-caspase inhibitor in experimental groups.Real-time PCR analysis showed a significant decrease in aromatase mRNA. The downregulation data was also confirmed using an ELISA estradiol kit. Acetylcholinesterase mRNA level was determined significantly reduced in siRNA-treated SH-SY5Y cells. It was observed that the specific activity of acetylcholinesterase was also reduced. Aromatase downregulation didn’t alter viability or caspase 3/7 activity of SHSY5Y cells. However, aromatase downregulation increased susceptibility to caspase-dependent apoptosis.Considering our findings, there may be interactions between aromatase and acetylcholinesterase that have not yet been elucidated and may contribute to the mechanism of chemobrain.

[1]  P. De,et al.  ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future. , 2019, American journal of cancer research.

[2]  Dusti A. Shay,et al.  Cognitive Effects of Aromatase and Possible Role in Memory Disorders , 2018, Front. Endocrinol..

[3]  T. Tüylü Küçükkılınç,et al.  Low‐dose bisphenol A induces RIPK1‐mediated necroptosis in SH‐SY5Y cells: Effects on TNF‐α and acetylcholinesterase , 2018, Journal of biochemical and molecular toxicology.

[4]  R. Gibbs,et al.  Effects of Cholinergic Lesions and Cholinesterase Inhibitors on Aromatase and Estrogen Receptor Expression in Different Regions of the Rat Brain , 2018, Neuroscience.

[5]  R. Elledge,et al.  Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers , 2018, Cell Death & Disease.

[6]  S. Lai,et al.  Nationwide Case-Control Study Examining the Association between Tamoxifen Use and Alzheimer’s Disease in Aged Women with Breast Cancer in Taiwan , 2017, Front. Pharmacol..

[7]  K. Helzlsouer,et al.  A prospective study of aromatase inhibitor therapy initiation and self-reported side effects , 2017, Supportive Care in Cancer.

[8]  F. Pasquier,et al.  A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy , 2015, Breast Cancer Research and Treatment.

[9]  Rena Li,et al.  Brain sex matters: Estrogen in cognition and Alzheimer’s disease , 2014, Molecular and Cellular Endocrinology.

[10]  Stephen M. Rao,et al.  Cognitive Performance among Breast Cancer Survivors Treated with Aromatase Inhibitors , 2013 .

[11]  S. Chow,et al.  Suppression of human T cell proliferation by the caspase inhibitors, z-VAD-FMK and z-IETD-FMK is independent of their caspase inhibition properties , 2012, Toxicology and applied pharmacology.

[12]  A. Contestabile.  The history of the cholinergic hypothesis , 2011, Behavioural Brain Research.

[13]  D. Small,et al.  Revisiting the Role of Acetylcholinesterase in Alzheimer’s Disease: Cross-Talk with P-tau and β-Amyloid , 2011, Front. Mol. Neurosci..

[14]  R. Gibbs,et al.  Donepezil plus estradiol treatment enhances learning and delay-dependent memory performance by young ovariectomized rats with partial loss of septal cholinergic neurons , 2011, Hormones and Behavior.

[15]  K. Phillips,et al.  Do aromatase inhibitors have adverse effects on cognitive function? , 2011, Breast Cancer Research.

[16]  A. Argyriou,et al.  Either called "chemobrain" or "chemofog," the long-term chemotherapy-induced cognitive decline in cancer survivors is real. , 2011, Journal of pain and symptom management.

[17]  I. Ábrahám,et al.  Action of estrogen on survival of basal forebrain cholinergic neurons: Promoting amelioration , 2009, Psychoneuroendocrinology.

[18]  V. Henderson.  Cognitive changes after menopause: influence of estrogen. , 2008, Clinical obstetrics and gynecology.

[19]  N. Teixeira,et al.  New steroidal aromatase inhibitors: Suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death , 2008, BMC Cell Biology.

[20]  B. Sherwin,et al.  Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: A critical review , 2008, Frontiers in Neuroendocrinology.

[21]  CharlesE. Roselli.  Brain aromatase: Roles in reproduction and neuroprotection , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[22]  H. Ploegh,et al.  z-VAD-fmk inhibits peptide:N-glycanase and may result in ER stress , 2006, Cell Death and Differentiation.

[23]  M. Corasaniti,et al.  From clinical evidence to molecular mechanisms underlying neuroprotection afforded by estrogens. , 2005, Pharmacological research.

[24]  A. Brodie,et al.  Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. , 2003, Cancer research.

[25]  L. Fallowfield,et al.  The effects of hormone therapy on cognition in breast cancer , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[26]  L. Garcia-Segura,et al.  Aromatase: a neuroprotective enzyme , 2003, Progress in Neurobiology.

[27]  J. Buccafusco,et al.  The Cholinergic Hypothesis of Age and Alzheimer's Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development , 2003, Journal of Pharmacology and Experimental Therapeutics.

[28]  V. Luine,et al.  Rapid enhancement of visual and place memory by estrogens in rats. , 2003, Endocrinology.

[29]  David A. Johnson,et al.  Estrogen enhances potassium-stimulated acetylcholine release in the rat hippocampus , 2003, Brain Research.

[30]  P. Berger,et al.  Estradiol decreases the acetylcholine-elicited airway reactivity in ovariectomized rats through an increase in epithelial acetylcholinesterase activity. , 2001, American journal of respiratory and critical care medicine.

[31]  N. Harada,et al.  Brain aromatase is neuroprotective. , 2001, Journal of neurobiology.

[32]  R. Gibbs.  Effects of gonadal hormone replacement on measures of basal forebrain cholinergic function , 2000, Neuroscience.

[33]  S. Tanada,et al.  Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: A positron emission tomography study , 2000, Annals of neurology.

[34]  I. Merchenthaler,et al.  Estrogen binding and estrogen receptor characterization (ERα and ERβ) in the cholinergic neurons of the rat basal forebrain , 2000, Neuroscience.

[35]  S Tanada,et al.  Brain Acetylcholinesterase Activity in Alzheimer Disease Measured by Positron Emission Tomography , 2000, Alzheimer disease and associated disorders.

[36]  J. Tschopp,et al.  Caspase Activation Is Required for T Cell Proliferation , 1999, The Journal of experimental medicine.

[37]  K. Davis,et al.  Cholinergic markers in elderly patients with early signs of Alzheimer disease. , 1999, JAMA.

[38]  S. Minoshima,et al.  In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease , 1999, Neurology.

[39]  G. Wilcock,et al.  The cholinergic hypothesis of Alzheimer’s disease: a review of progress , 1999, Journal of neurology, neurosurgery, and psychiatry.

[40]  P. Vandenabeele,et al.  Non‐specific effects of methyl ketone peptide inhibitors of caspases , 1999, FEBS letters.

[41]  M. Shapira,et al.  Human Osteogenesis Involves Differentiation-Dependent Increases in the Morphogenically Active 3′ Alternative Splicing Variant of Acetylcholinesterase , 1999, Molecular and Cellular Biology.

[42]  G. Dohanich,et al.  Estrogen Enhances Performance of Female Rats during Acquisition of a Radial Arm Maze , 1997, Hormones and Behavior.

[43]  L. Schneider,et al.  Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease , 1996, Neurology.

[44]  V. Luine,et al.  Gonadal hormone regulation of MAO and other enzymes in hypothalamic areas. , 1983, Neuroendocrinology.

[45]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[46]  L. Kanerva,et al.  Histochemically demonstrable catecholamines and cholinesterases of the rat uterus during estrus cycle, pregnancy and after estrogen treatment. , 1973, Acta physiologica Scandinavica.

[47]  R. D. Jacobs,et al.  The influence of estradiol-17β on cholinesterase activity in the lung , 1970 .

[48]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.